Unlocking the Mystery of Rare Diseases: The Power of Alternate Proteins
The genetic puzzle of rare diseases is far from complete. While we've identified many disease-causing mutations, a staggering 70% of patients still lack a clear genetic explanation. But what if the key lies in looking beyond the 'known' proteins? A recent study published in Molecular Cell on November 7th (https://www.cell.com/molecular-cell/fulltext/S1097-2765(25)00854-8) suggests that the answer might be hidden in the alternate proteins produced by the same gene.
It's commonly believed that each gene codes for a single protein, and researchers often focus on mutations affecting this known protein. But here's the twist: most genes can code for multiple proteins. So, a mutation that seems harmless to the known protein might actually disrupt a different protein from the same gene, potentially contributing to disease. And this is the part most people miss—the same mutation can have varying effects depending on which protein it impacts.
The research team, led by Iain Cheeseman and Jimmy Ly from the Whitehead Institute for Biomedical Research, delved into this phenomenon. They discovered that cells have evolved a clever mechanism to generate different protein versions from the same gene, and these variations play a crucial role in health and disease. But how does this work?
Cells employ several strategies to create protein diversity, and one fascinating method involves alternate starting points during protein production. Cellular machinery follows genetic instructions, starting at a 'start codon' and ending at a 'stop codon'. However, some genes contain multiple start codons, and the machinery might skip the first one and use a second one, creating a shorter protein. Alternatively, it may detect a sequence resembling a start codon earlier in the genetic sequence, resulting in a longer protein.
This isn't a mistake; it's a sophisticated process conserved across species. Ly traced the evolution of genes producing multiple proteins and found it to be a robust mechanism that has endured for millions of years. One of its functions is to direct proteins to specific locations within the cell. Longer and shorter protein versions can have different 'ZIP code-like' sequences, determining their destination. Ly discovered that this can lead to significant consequences.
In some cases, one protein version ends up in mitochondria, the cell's energy factories, while another goes elsewhere. Mutations in mitochondrial genes are often linked to diseases. Ly's curiosity led him to explore what happens when a mutation affects only one protein version, leaving the other intact. He found numerous cases in a rare disease database, suggesting that such mutations might be more common than we think. But without access to the patients, the full impact on their health remained a mystery.
Cheeseman and Ly's collaboration with Mark Fleming, a pathologist at Boston Children's Hospital, brought this research to life. They studied patients with a rare anemia called SIFD, caused by mutations in the TRNT1 gene. This gene produces two protein versions: one for mitochondria and another for the nucleus. Fleming's patient data revealed intriguing cases. Most patients had mutations affecting both protein versions, but two patients had mutations targeting only one version, leading to very different disease presentations.
One patient with the mitochondrial protein version intact had anemia but no developmental delays. The other, lacking the mitochondrial version, had immune symptoms and was misdiagnosed for decades. Ly's work sheds light on these atypical symptoms, emphasizing the importance of considering multiple protein versions in disease diagnosis and treatment.
The researchers are now developing a tool called SwissIsoform to help clinicians identify mutations affecting specific protein versions. This tool will ensure that mutations with varying impacts are not overlooked. Fleming highlights the potential impact, citing recent cases of patients with milder symptoms due to mutations affecting only mitochondrial protein versions.
In the long term, these discoveries could revolutionize our understanding of diseases and gene therapies. But in the short term, they offer hope to clinicians and patients by providing valuable insights into rare diseases. Cheeseman reflects on the satisfaction of knowing that basic research can directly impact people's lives, motivating his team to continue unraveling the complexities of disease biology.
